Product/Service Development

Aims to validate the International Fetal and Newborn Growth Consortium for the 21st century (Intergrowth-21st) standards for gestational weight gain (GWG) and create new recommendations of GWG based on those standards for first trimester normal and overweight women to be used in the Brazilian Unified Health System (SUS). GWG recommendations currently used in SUS have not been properly tested or validated, thus the project might improve prenatal nutritional care and reduce post gestational weight retention.

The project will develop a cellulose filter containing immobilized DNA aptamers, molecules that bind to a specific target molecule, that act as specific and high affinity probes for the uptake and retention of antibiotic molecules present in effluents. Nowadays, the removal of antibiotic residues from effluents is mainly based on chemical processes and physical methods that require expensive technologies and costly maintenance. The success of this project will represent a wastewater treatment option that is low-cost and environment-friendly.

The project proposes to use an aerobic granular sludge (AGS) - a technology based on microbial community - to remove antibiotics and antimicrobial resistant genes from hospital wastewater. AGS is one of the latest innovations and it has not yet been applied for the treatment of hospital wastewater.

This project proposes the development of the One Health Brazilian Resistance (OneBR), a curated and integrated genomic database. OneBR will use algorithms based on artificial intelligence to conduct surveillance, diagnosis, management and treatment of antimicrobial resistance (AMR) in the human-animal-environment interface. The goal is for this platform to be used by Brazilian health professionals in diverse settings, particularly within the Unified Healthcare System (SUS).

The idea is to develop an artificial intelligence model capable of simultaneously analyzing data from the Laboratory Information System and from the Hospital Information System. This technology aims to enable the delivery to hospital physicians of a ranked list of antimicrobials that are more suitable to treat infection by multi-resistant microorganism with a focus on newborn and young children.

Patricia Donahoe and David Pepin of Massachusetts General Hospital in the U.S. are using a cell-based screening platform to develop a new class of hormonal contraceptive that works at the early stage of primordial follicle activation to prolong the contraceptive effect and reduce side effects, thereby promoting wider use particularly in the developing world. This early stage of follicle development in the ovary is suppressed by a hormone (Mullerian inhibiting substance or MIS) to regulate egg production.

Joseph Culver of Washington University in St Louis in the U.S. is developing a portable, optical neuroimaging technology (high-density diffuse optical tomography [HD-DOT]) to monitor the effects of malnutrition on brain development in young children in low-resource settings. During the first ten years of life, the brain develops many skills such as visual and language processing, and has unique nutritional requirements.

Stéphane Blanc of the Institut National de la Recherche Agronomique (INRA) in France will minimize the destructive effects of aphids on crop plants by studying a newly described structure, the acrostyle, which is found at the tip of the piercing mouthparts of the insects and thought to be important for feeding and for transmitting disease-causing viruses between plants. Aphids spread an array of different plant viruses to many crop species including banana, chickpea, and sweet potato.

David Anderson of the Macfarlane Burnet Institute for Medical Research in Australia will develop a low-cost, simple to use, sample collection device to improve sample quality and ensure accurate and timely diagnosis in remote, low-resource areas. Obtaining high quality serum samples needed for diagnosing a variety of diseases is challenging in these regions due to the lack of equipment and expertise to process the samples and stabilize them for transport to the diagnostic laboratories.

William Grover of the University of California, Riverside, in the U.S. will create a medical record that is permanently attached to its human sample using micron-sized microtransponder chips added to the samples during collection. These chips will permanently link the sample to the patient, and provide their contact details, when and where the sample was collected, and the test results.